Treatment Approach for Panniculitis

Diagnosis and Classification

The American Thoracic Society recommends obtaining a deep excisional biopsy with adequate tissue for histopathological evaluation to diagnose panniculitis, as superficial biopsies may miss the pathology in medium-sized vessels of the dermis 1, 2
Testing for alpha-1 antitrypsin deficiency is recommended in all cases of biopsy-proven severe panniculitis, particularly in factitious and necrotizing cases, according to the American College of Chest Physicians 1, 3
Imaging studies, such as those recommended by the European Society for Medical Oncology, can be used to evaluate the extent of disease, especially in cases with subcutaneous presentation 4

The American Thoracic Society recommends augmentation therapy with purified human AAT or fresh frozen plasma as the most effective treatment for alpha-1 antitrypsin deficiency-associated panniculitis, as it restores plasma and local tissue levels of AAT 1, 3
Dapsone may be beneficial, either alone in less severe cases or combined with augmentation therapy, according to the American College of Chest Physicians 1, 3
Family screening and antismoking counseling are essential components of management, as recommended by the American Thoracic Society 1, 3
Liver transplantation has led to permanent cure in severe cases by restoring plasma AAT levels, according to the American Association for the Study of Liver Diseases 1, 3

The American College of Rheumatology recommends treatment with cyclophosphamide and high-dose glucocorticoids for polyarteritis nodosa with cutaneous involvement 5, 2
For severe disease, the American College of Rheumatology recommends initiating treatment with intravenous pulse glucocorticoids over high-dose oral glucocorticoids 5, 2
In patients unable to tolerate cyclophosphamide, other non-glucocorticoid immunosuppressive agents should be considered, according to the American College of Rheumatology 2

Treatment should address both the hemophagocytic lymphohistiocytosis and the underlying neoplasm in panniculitis associated with malignancy, as recommended by the European Hematology Association 6
Cyclosporin A has shown efficacy in clonal cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic lymphohistiocytosis, according to the European Society for Medical Oncology 6

The American College of Rheumatology recommends follow-up abdominal vascular imaging for patients with a history of severe panniculitis with abdominal involvement who become clinically asymptomatic 5, 2
Serial neurologic examinations are preferred over repeated electromyography/nerve conduction studies for patients with peripheral motor neuropathy secondary to panniculitis, according to the American Academy of Neurology 2

Inadequate biopsy depth is a common pitfall in diagnosis, and deep excisional specimens should be obtained, as recommended by the American Thoracic Society 1, 3
Panniculitis can be lethal, especially when associated with other complications such as cirrhosis or emphysema in AAT deficiency, according to the American Association for the Study of Liver Diseases 1, 3

The American Society of Clinical Oncology recommends treating Subcutaneous Panniculitis-Like T-Cell Lymphoma without hemophagocytic syndrome with systemic steroids or other immunosuppressive agents first, with a 5-year survival rate of 91% 7
The American Society of Clinical Oncology recommends treating Subcutaneous Panniculitis-Like T-Cell Lymphoma with hemophagocytic syndrome with immediate multi-agent chemotherapy, with a 5-year survival rate of 46% 7
The Infectious Diseases Society of America recommends treating Infectious Panniculitis (Nocardia) with SMX-TMP as first-line therapy, with alternative agents including sulfadiazine, sulfasoxazole, amikacin, imipenem, meropenem, ceftriaxone, cefotaxime, minocycline, moxifloxacin, linezolid, or dapsone 8
The Infectious Diseases Society of America recommends continuing treatment for Infectious Panniculitis (Nocardia) for 6-24 months, depending on the extent of dissemination and degree of immunosuppression 8
The Infectious Diseases Society of America recommends performing surgical debridement for necrotic nodules or large subcutaneous abscesses in Infectious Panniculitis (Nocardia) 8

Primary treatment focuses on controlling the underlying disease (e.g., inflammatory bowel disease flare); systemic corticosteroids are reserved for severe EN, and immunomodulators such as azathioprine, infliximab, or adalimumab are used for resistant or relapsing cases – Journal of Crohn’s and Colitis recommendation 9.
Typical clinical presentation: tender, raised, red‑violet subcutaneous nodules 1–5 cm in diameter located on extensor surfaces, especially the anterior lower‑leg region – observed in cohort studies [10][9].
Diagnosis is usually clinical; when a biopsy is performed, histology shows a non‑specific focal panniculitis – supported by case series [10][9].
Treatment algorithm
- First‑line: address the precipitating condition (e.g., treat active IBD) 9.
- Second‑line: administer systemic corticosteroids for severe EN [10][9].
- Third‑line: employ immunomodulators (azathioprine, infliximab, adalimumab) for cases that are resistant or experience frequent relapses [10][9].
Evidence level: not explicitly graded in the source; recommendations are based on expert consensus and observational data.

Management must simultaneously target hemophagocytic lymphohistiocytosis (HLH) and the underlying neoplasm – Haematologica guideline 11.
Cyclosporine A has demonstrated efficacy in clonal cytophagic histiocytic panniculitis and in subcutaneous panniculitis‑like T‑cell lymphoma with HLH features – clinical evidence reported 11.
Evidence level: derived from case‑series and retrospective analyses; formal grading not provided.